We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-18.21%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$12.2B
AUM Growth
-$2.97B
Cap. Flow
+$24.4M
Cap. Flow %
0.2%
Top 10 Hldgs %
86.1%
Holding
101
New
4
Increased
12
Reduced
21
Closed
10

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$219M
2
AMRN
Amarin Corp
AMRN
+$155M
3
KOD icon
Kodiak Sciences
KOD
+$81M
4
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$22.3M
5
KRYS icon
Krystal Biotech
KRYS
+$14M

Top Sells

Rank Stock Value
1
GHDX
Genomic Health, Inc.
GHDX
+$143M
2
SAGE
Sage Therapeutics
SAGE
+$80.2M
3
NVTA
Invitae Corporation
NVTA
+$58.3M
4
ECYT
Endocyte, Inc. Common Stock
ECYT
+$45.3M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$21.5M

Sector Composition

Rank Sector Weight
1 Healthcare 92.2%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FSTX
51
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$6.37M 0.05%
153,286
– –
ALBO
52
DELISTED
Albireo Pharma Inc
ALBO
$6.13M 0.05%
250,000
– –
CPRX
53
DELISTED
Catalyst Pharmaceutical
CPRX
$5.57M 0.05%
2,900,000
– –
AUTL
54
Autolus Therapeutics
AUTL
$389M
$5.15M 0.04%
156,773
-78,521
-33% -$2.58M
HALO icon
55
Halozyme
HALO
$9.88B
$4.39M 0.04%
299,969
-150,000
-33% -$2.39M
BLUE
56
DELISTED
bluebird bio
BLUE
$3.97M 0.03%
3,088
-1,501
-33% -$2.3M
CRNX icon
57
Crinetics Pharmaceuticals
CRNX
$8.88B
$3.94M 0.03%
131,250
– –
FTSV
58
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$3.93M 0.03%
250,000
– –
XLRN
59
DELISTED
Acceleron Pharma
XLRN
$3.65M 0.03%
83,900
– –
ASMB icon
60
Assembly Biosciences
ASMB
$498M
$3.36M 0.03%
12,382
– –
VKTX icon
61
Viking Therapeutics
VKTX
$3.88B
$3.25M 0.03%
425,000
– –
SYRS
62
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$3.2M 0.03%
57,484
– –
VYNE icon
63
VYNE Therapeutics
VYNE
$2.88M 0.02%
194
– –
GNMX
64
DELISTED
Aevi Genomic Medicine Inc
GNMX
$2.77M 0.02%
3,950,419
– –
SRRA
65
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$2.64M 0.02%
+50,000
New +$3.19M
APLS
66
DELISTED
Apellis Pharmaceuticals
APLS
$2.59M 0.02%
196,078
– –
GTHX
67
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$2.44M 0.02%
127,236
– –
LKFT
68
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$2.3M 0.02%
25,072
-212,119
-89% -$21.5M
CCXI
69
DELISTED
ChemoCentryx, Inc.
CCXI
$2.26M 0.02%
207,029
-207,000
-50% -$2.18M
YMAB
70
DELISTED
Y-mAbs Therapeutics
YMAB
$2.09M 0.02%
102,800
-47,200
-31% -$1.08M
ALKS icon
71
Alkermes
ALKS
$8.11B
$1.98M 0.02%
67,000
-33,251
-33% -$1.23M
ORTX
72
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$1.97M 0.02%
+12,500
New +$1.86M
FOMX
73
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.79M 0.01%
498,189
-189,886
-28% -$826K
NTLA icon
74
Intellia Therapeutics
NTLA
$1.51B
$1.75M 0.01%
128,538
-64,000
-33% -$1.19M
ACHN
75
DELISTED
Achillion Pharmaceuticals
ACHN
$1.74M 0.01%
1,095,359
-544,589
-33% -$1.54M
1 2
3
4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2018 Portfolio in Review

As of Q4 2018, Baker Bros. Advisors held 101 positions worth $12.2B, down 20% from $15.2B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Baker Bros. Advisors's Q4 2018 filing shows 4 new, 12 increased, 21 reduced and 10 closed positions. Its largest new stake was Kodiak Sciences: 9,145,115 shares worth $64.9M. The largest sale was Genomic Health, Inc., an estimated $143M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 91% a quarter earlier, followed by Technology.

  • Baker Bros. Advisors's largest Q4 2018 buy was Kodiak Sciences: 9,145,115 shares worth $64.9M.
  • Baker Bros. Advisors added most to Acadia Pharmaceuticals in Q4 2018, an estimated $219M increase.
  • Baker Bros. Advisors's biggest Q4 2018 reduction was Genomic Health, Inc., cutting an estimated $143M.
  • Baker Bros. Advisors fully exited Sage Therapeutics in Q4 2018, selling an estimated $80.2M.
  • Baker Bros. Advisors's ten largest holdings make up 86% of its $12.2B portfolio in Q4 2018.
  • Baker Bros. Advisors opened 4 new positions and closed 10 in Q4 2018.
  • Baker Bros. Advisors's portfolio value fell 20% quarter-over-quarter to $12.2B.

Based on Baker Bros. Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.